A New Rapid-Acting Antidepressant

John H. Krystal; Dennis S. Charney; Ronald S. Duman

doi:10.1016/j.cell.2020.02.033

A New Rapid-Acting Antidepressant

John H. Krystal, Dennis S. Charney, Ronald S. Duman

Research output: Contribution to journal › Comment/debate

21 Scopus citations

Abstract

The discovery of the strikingly rapid and robust antidepressant effects of r/s-ketamine for the treatment of antidepressant-resistant symptoms of depression has led to new insights into the biology of antidepressants and the FDA approval of its s-isomer, Esketamine (Spravato), the first mechanistically new treatment for depression in over 60 years. To view this Bench to Bedside, open or download the PDF.

Original language	English
Pages (from-to)	7
Number of pages	1
Journal	Cell
Volume	181
Issue number	1
DOIs	https://doi.org/10.1016/j.cell.2020.02.033
State	Published - 2 Apr 2020
Externally published	Yes

Access to Document

10.1016/j.cell.2020.02.033

Cite this

@article{209c61418794435980f2b554162ead9c,

title = "A New Rapid-Acting Antidepressant",

abstract = "The discovery of the strikingly rapid and robust antidepressant effects of r/s-ketamine for the treatment of antidepressant-resistant symptoms of depression has led to new insights into the biology of antidepressants and the FDA approval of its s-isomer, Esketamine (Spravato), the first mechanistically new treatment for depression in over 60 years. To view this Bench to Bedside, open or download the PDF.",

author = "Krystal, {John H.} and Charney, {Dennis S.} and Duman, {Ronald S.}",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2020",

month = apr,

day = "2",

doi = "10.1016/j.cell.2020.02.033",

language = "English",

volume = "181",

pages = "7",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - A New Rapid-Acting Antidepressant

AU - Krystal, John H.

AU - Charney, Dennis S.

AU - Duman, Ronald S.

PY - 2020/4/2

Y1 - 2020/4/2

N2 - The discovery of the strikingly rapid and robust antidepressant effects of r/s-ketamine for the treatment of antidepressant-resistant symptoms of depression has led to new insights into the biology of antidepressants and the FDA approval of its s-isomer, Esketamine (Spravato), the first mechanistically new treatment for depression in over 60 years. To view this Bench to Bedside, open or download the PDF.

AB - The discovery of the strikingly rapid and robust antidepressant effects of r/s-ketamine for the treatment of antidepressant-resistant symptoms of depression has led to new insights into the biology of antidepressants and the FDA approval of its s-isomer, Esketamine (Spravato), the first mechanistically new treatment for depression in over 60 years. To view this Bench to Bedside, open or download the PDF.

UR - http://www.scopus.com/inward/record.url?scp=85082421198&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2020.02.033

DO - 10.1016/j.cell.2020.02.033

M3 - Comment/debate

C2 - 32243798

AN - SCOPUS:85082421198

SN - 0092-8674

VL - 181

SP - 7

JO - Cell

JF - Cell

IS - 1

ER -

A New Rapid-Acting Antidepressant

Abstract

Access to Document

Fingerprint

Cite this